XLO — Xilio Therapeutics Share Price
Last trade - 00:00- $35.81m
- $1.83m
- 12
- 22
- 45
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.3 | ||
| Price to Tang. Book | 1.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -143.25% | ||
| Return on Equity | -128.37% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 15 | 37.5 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.
Directors
- Daniel Lynch CHM
- Timothy Clackson PRE (54)
- Rene Russo CEO (46)
- Salvatore Giovine CFO
- Joseph Farmer COO
- Ronan O'Hagan SVP
- Chris Frankenfield GCN
- Yuan Xu DRC
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 1st, 2016
- Public Since
- October 22nd, 2021
- No. of Shareholders
- 35
- No. of Employees
- 73
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 36,912,373
- Address
- 828 Winter Street, Suite 300, WALTHAM, 02451
- Web
- https://xiliotx.com/
- Phone
- +1 6174304680
- Auditors
- Ernst & Young LLP
Upcoming Events for XLO
Similar to XLO
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 24:12 UTC, shares in Xilio Therapeutics are trading at $0.91. This share price information is delayed by 15 minutes.
Shares in Xilio Therapeutics last closed at $0.91 and the price had moved by -66.6% over the past 365 days. In terms of relative price strength the Xilio Therapeutics share price has underperformed the S&P500 Index by -73.43% over the past year.
The overall consensus recommendation for Xilio Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Xilio Therapeutics does not currently pay a dividend.
Xilio Therapeutics does not currently pay a dividend.
Xilio Therapeutics does not currently pay a dividend.
To buy shares in Xilio Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.91, shares in Xilio Therapeutics had a market capitalisation of $33.53m.
Here are the trading details for Xilio Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: XLO
Based on an overall assessment of its quality, value and momentum Xilio Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Xilio Therapeutics is $5.50. That is 505.46% above the last closing price of $0.91.
Analysts covering Xilio Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.40 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xilio Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +49.2%.
As of the last closing price of $0.91, shares in Xilio Therapeutics were trading -24.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Xilio Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Xilio Therapeutics' management team is headed by:
- Daniel Lynch - CHM
- Timothy Clackson - PRE
- Rene Russo - CEO
- Salvatore Giovine - CFO
- Joseph Farmer - COO
- Ronan O'Hagan - SVP
- Chris Frankenfield - GCN
- Yuan Xu - DRC